Cancer-specific and net overall survival in older patients with de novo metastatic prostate cancer initially treated with androgen deprivation therapy.
Shintaro NaritaNaoki TeradaKyoko NomuraShinichi SakamotoShingo HatakeyamaTakuma KatoYoshiyuki MatsuiJunichi InokuchiAkira YokomizoKen-Ichi TabataMasaki ShiotaTakahiro KimuraTakahiro KojimaTakahiro InoueTakashi MizowakiMikio SugimotoHiroshi KitamuraToshiyuki KamotoHiroyuki NishiyamaTomonori Habuchinull nullPublished in: International journal of urology : official journal of the Japanese Urological Association (2022)
Older metastatic prostate cancer patients aged ≥80 years had poorer cancer-specific survival compared with younger patients. Conversely, 5-year net overall survival in older patients aged ≥80 years was comparable with that in younger patients aged <75 years.
Keyphrases
- prostate cancer
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- squamous cell carcinoma
- small cell lung cancer
- prognostic factors
- peritoneal dialysis
- papillary thyroid
- squamous cell
- free survival
- physical activity
- young adults
- benign prostatic hyperplasia
- lymph node metastasis
- smoking cessation
- cell therapy